» Articles » PMID: 36327269

DNA Damage and Antioxidant Capacity in COPD Patients with and Without Lung Cancer

Overview
Journal PLoS One
Date 2022 Nov 3
PMID 36327269
Authors
Affiliations
Soon will be listed here.
Abstract

Background And Objective: Chronic obstructive pulmonary disease (COPD) is characterized by chronic inflammation of the lower airways, and COPD patients show two to five times higher risk of lung cancer than smokers with normal lung function. COPD is associated with increased oxidative stress, which may cause DNA damage and lung carcinogenesis. Our aim was to evaluate DNA damage and oxidative stress (lipid peroxidation and antioxidant status) and their relationship in patients with COPD with and without lung cancer.

Methods: We evaluated 18 patients with COPD, 18 with COPD with lung cancer, and 18 controls (former or current smokers). DNA damage was evaluated in peripheral blood lymphocytes using a comet assay; the concentration of malondialdehyde (MDA) and hydrophilic antioxidant performance (HAP) were measured in the plasma.

Results: DNA damage was higher in patients with COPD with cancer than in the controls (p = 0.003). HAP was significantly lower in patients with COPD with cancer than in those without cancer and controls. The presence of lung cancer and COPD showed a positive association with DNA strand breaks and the concentration of MDA.

Conclusion: COPD with lung cancer was associated with elevated DNA damage in peripheral lymphocytes, and cancer and COPD showed a positive correlation with DNA damage. The antioxidant capacity showed a negative association with the interaction COPD and cancer and presence of COPD. The mechanisms underlying the increased incidence of lung cancer in COPD are unknown; DNA damage may be involved. Further research may provide insights into their development and treatment.

Citing Articles

A Comprehensive Review of Advances in Molecular Mechanisms and Targeted Therapies for the Specific Type of Cystic Lung Cancer.

Wang B, Shen C, Liu D, Dong Z, Lin X, Liao H Onco Targets Ther. 2025; 18:211-224.

PMID: 39959914 PMC: 11829588. DOI: 10.2147/OTT.S495018.


Implications of DNA damage in chronic lung disease.

Zhang D, Sun T, Bao J, Fu J Front Cell Dev Biol. 2024; 12:1436767.

PMID: 39544366 PMC: 11560874. DOI: 10.3389/fcell.2024.1436767.


Applications and advancements of nanoparticle-based drug delivery in alleviating lung cancer and chronic obstructive pulmonary disease.

De Rubis G, Paudel K, Corrie L, Mehndiratta S, Patel V, Kumbhar P Naunyn Schmiedebergs Arch Pharmacol. 2023; 397(5):2793-2833.

PMID: 37991539 DOI: 10.1007/s00210-023-02830-w.


The Role of Oxidative Stress and Antioxidants in Cardiovascular Comorbidities in COPD.

Miklos Z, Horvath I Antioxidants (Basel). 2023; 12(6).

PMID: 37371927 PMC: 10295232. DOI: 10.3390/antiox12061196.


Mucolytic and Antioxidant Properties of Carbocysteine as a Strategy in COVID-19 Therapy.

Bianco A, Conte S, Mariniello D, Allocca V, Matera M, DAgnano V Life (Basel). 2022; 12(11).

PMID: 36362979 PMC: 9692377. DOI: 10.3390/life12111824.

References
1.
Tang J, Curull V, Wang X, Ampurdanes C, Duran X, Pijuan L . Increased PARP Activity and DNA Damage in NSCLC Patients: The Influence of COPD. Cancers (Basel). 2020; 12(11). PMC: 7697659. DOI: 10.3390/cancers12113333. View

2.
Caramori G, Adcock I, Casolari P, Ito K, Jazrawi E, Tsaprouni L . Unbalanced oxidant-induced DNA damage and repair in COPD: a link towards lung cancer. Thorax. 2011; 66(6):521-7. DOI: 10.1136/thx.2010.156448. View

3.
Vasiljevic S, Petrovic M, Cvetkovic A, Mikic D, Paunovic V . Relationship between incidence of chronic obstructive pulmonary disease and lung cancer as comorbidity in primary health care in two Belgrade communities. J BUON. 2019; 24(3):963-966. View

4.
Bozinovski S, Vlahos R, Anthony D, McQualter J, Anderson G, Irving L . COPD and squamous cell lung cancer: aberrant inflammation and immunity is the common link. Br J Pharmacol. 2015; 173(4):635-48. PMC: 4742298. DOI: 10.1111/bph.13198. View

5.
Spirlandeli A, Deminice R, Jordao A . Plasma malondialdehyde as biomarker of lipid peroxidation: effects of acute exercise. Int J Sports Med. 2013; 35(1):14-8. DOI: 10.1055/s-0033-1345132. View